文献速递前列腺癌

术前风险对根治性前列腺切除术后不良病理患者转移进展和前列腺癌特异性死亡的影响

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
PubMed 文献 · BJU Int · 2017-05-29

该研究分析欧洲三级中心6943例根治性前列腺切除术患者,按术前低危与中/高危分层,评估不良病理患者的生化复发、转移和前列腺癌特异性死亡。结果显示低危患者在上述不良病理亚组中转移率和前列腺癌特异性死亡率均显著低于中/高危患者,低危状态是转移和前列腺癌特异性死亡的预测因素。

要点

  • 包膜外侵犯患者10年转移率低危1.6% vs 中/高危8%(P<0.001),前列腺癌特异性死亡率2% vs 5%(P=0.041)。
  • 病理Gleason评分≥3+4患者转移率低危3.0% vs 中/高危12%(P<0.001),前列腺癌特异性死亡率3% vs 8%(P<0.001)。
  • 手术切缘阳性患者转移率低危2.9% vs 中/高危15%(P<0.001),前列腺癌特异性死亡率4% vs 10%(P=0.0001)。

核心结论

  • 根治性前列腺切除术发现不良病理特征时,术前低危前列腺癌患者的转移疾病和前列腺癌特异性死亡风险显著低于中/高危患者。
  • 这一差异应在根治性前列腺切除术后的决策过程中予以强调。

研究设计与样本

  • 回顾性分析欧洲三级中心6943例接受根治性前列腺切除术的患者记录。
  • 按术前低危与中/高危前列腺癌分组,评估不良病理患者的生化复发、转移疾病和前列腺癌特异性死亡。
  • 采用Kaplan-Meier、累积发生率、Cox回归和竞争风险回归分析。

主要发现

  • 包膜外侵犯患者10年转移率低危1.6% vs 中/高危8%(P<0.001),前列腺癌特异性死亡率2% vs 5%(P=0.041)。
  • 病理Gleason评分≥3+4患者转移率低危3.0% vs 中/高危12%(P<0.001),前列腺癌特异性死亡率3% vs 8%(P<0.001)。
  • 手术切缘阳性患者转移率低危2.9% vs 中/高危15%(P<0.001),前列腺癌特异性死亡率4% vs 10%(P=0.0001)。
  • 低危状态是病理Gleason评分≥3+4患者转移疾病的预测因素(HR 0.51),也是病理Gleason评分≥4+3(HR 0.41)和手术切缘阳性(HR 0.46)患者转移疾病的预测因素。
  • 低危状态是病理Gleason评分≥3+4患者前列腺癌特异性死亡风险的预测因素(HR 0.62)。

临床怎么用

  • 原文结论指出,根治性前列腺切除术后发现不良病理特征时,术前低危患者的转移和前列腺癌特异性死亡风险显著低于中/高危患者,这一差异应在术后决策过程中予以强调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP). PATIENTS AND METHODS: The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan-Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed. RESULTS: In patients with extracapsular extension, the metastatic disease rate was 1.6% vs 8% (P < 0.001) and the CSM rate was 2% vs 5% (P = 0.041) for low vs intermediate-/high-risk patients, respectively, at 10 years. In patients with pathological Gleason score ≥3+4, the metastatic disease rate was 3.0% vs 12% (P < 0.001) and the CSM rate was 3% vs 8%, respectively (P < 0.001). In patients with positive surgical margins (PSMs), the metastatic disease rate was 2.9% vs 15% (P < 0.001) and the CSM rate was 4% vs 10%, respectively (P = 0.0001). Low-risk status was a predictive factor for metastatic disease in patients with pathological Gleason score ≥3+4 (hazard ratio [HR] 0.51), pathological Gleason score ≥4+3 (HR 0.41) and PSMs (HR 0.46) and was a predictive factor for CSM risk in patients with pathological Gleason score ≥3+4 (HR 0.62). CONCLUSIONS: Patients with low-risk PCa were at significantly lower risk of metastatic disease and CSM than their intermediate-/high-risk counterparts, when adverse pathological features were identified at RP. This should be emphasized in the decision-making process after RP.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Boehm K, Leyh-Bannurah SR, Rosenbaum C, et al. Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. BJU Int. 2017. PMID: 28437038. doi:10.1111/bju.13887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。